MedTrace Logo

Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)

NCT00936247 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2010-09-28

No results posted yet for this study

Summary

This investigational study will investigate two different volume replacement regimes in patients suffering from compromised renal function.

Conditions

  • Renal Insufficiency

Interventions

DRUG

HES 130/0.42 + electrolyte solution

Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component

DRUG

Albumin + electrolyte solution

Albumin 5% as colloid component and NaCl 0.9% as electrolyte component

Sponsors & Collaborators

  • B. Braun Melsungen AG

    lead INDUSTRY

Principal Investigators

  • Thomas Lücke, Prof. Dr. · Klinikum Mannheim gGmbH, Klink für Anästhesiologie und Operative Intensivmedizin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936247 on ClinicalTrials.gov